Relapse of thrombotic thrombocytopenic purpura: Is it a continuum of disease?

Seminars in Thrombosis and Hemostasis

Volumn 31, Issue 6, 2005, Pages 700-708

  Willis, Monte S ^b   Bandarenko, Nicholas ^a,b  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Adjunct therapy; Prognostic factors; Relapse; Thrombotic thrombocytopenic purpura (TTP)

Indexed keywords

ANTIBIOTIC AGENT; ANTITHROMBOCYTIC AGENT; CORTICOSTEROID; CYCLOSPORIN; DOXYCYCLINE; ENZYME INHIBITOR; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; PROSORBA; RITUXIMAB; STAPHYLOCOCCUS PROTEIN A; TACROLIMUS; TICLOPIDINE; UNCLASSIFIED DRUG; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE INHIBITOR;

CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; ENZYME ACTIVITY; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; PATHOPHYSIOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RELIABILITY; REMISSION; REVIEW; SPLENECTOMY; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT FAILURE; TREATMENT OUTCOME;

ADAM PROTEINS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; L-LACTATE DEHYDROGENASE; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; REMISSION INDUCTION; SPLENECTOMY; VINCRISTINE;

EID: 30344433272     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-925476     Document Type: Review

References (64)

1. Sadler JE, Moake JL, Miyata T, George JN. Recent advances in thrombotic thrombocytopenic purpura. Hematology (Am Soc Hematol Educ Program) 2004;1:407-423
2. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000; 96:1223-1229
3. Shumak KH, Rock GA, Nair RC. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Ann Intern Med 1995;122: 569-572
4. Bandarenko N, Brecher ME. United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. J Clin Apheresis 1998;13:133-141
5. Egan JA, Hay SN, Brecher ME. Frequency and significance of schistocytes in TTP/HUS patients at the discontinuation of plasma exchange therapy. J Clin Apheresis 2004;19: 165-167
6. Committee AET. Guidelines for Therapeutic Hemapheresis. Bethesda, MD: American Association of Blood Banks; 1993
7. Gilcher RO, Strauss RG, Ciavarella D, et al. Management of renal disorders. J Clin Apheresis 1993;8:258-269
8. Downes KA, Yomtovian R, Tsai HM, Silver B, Rutherford C, Sarode R. Relapsed thrombotic thrombocytopenic purpura presenting as an acute cerebrovascular accident. J Clin Apheresis 2004;19:86-89
9. Furlan M, Robles R, Morselli B, Sandoz P, Lammle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1999;81:8-13
10. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004;103:4043-4049
11. Rock G, Anderson D, Clark W, et al. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. Br J Haematol 2005;129:79-86
12. Rock G. Thrombotic thrombocytopenic purpura: Current therapies and diagnostic tools. J Clin Apheresis 2005;20:9 (abst)
13. George JN, Vesely SK, Terrell DR. The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol 2004;41:60-67
14. Rock G, Shumak KH, Sutton DM, Buskard NA, Nair RC. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group. Br J Haematol 1996;94:383-386
15. Lakey MA, Boctor FN, Knight CW, Marques MB. VWF-cleaving protease activity and inhibitor levels do not predict duration of treatment in TTP and HUS. J Clin Apheresis 2005;20:7 (abst)
16. Egan JA, Hay SN, Millward PA, Bandarenko N, Brecher ME. Effect of discontinuation of plasma exchange in pseudo-refractory thrombotic thrombocytopenic purpura patients. J Clin Apheresis 2005;20:8 (abst)
17. Hay SH, Egan JA, Millward PA. Declining platelet counts in TTP patients receiving daily plasma exchange: frequency and Outcome. J Clin Apheresis 2005;20:10 (abst)
18. Tsai HM, Rice L, Sarode R, Chow TW, Moake JL. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 2000;132:794-799
19. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-1594
20. Reutter JC, Sanders KF, Brecher ME, Jones HG, Bandarenko N. Incidence of allergic reactions with fresh frozen plasma or cryo-supernatant plasma in the treatment of thrombotic thrombocytopenic purpura. J Clin Apheresis 2001;16:134-138
21. Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis 1994;23: 817-827
22. Sutton DM, Nair RC, Rock G. Complications of plasma exchange. Transfusion 1989;29:124-127
23. McLeod BC, Sniecinski I, Ciavarella D, et al. Frequency of immediate adverse effects associated with therapeutic apheresis. Transfusion 1999;39:282-288
24. Schneider PA, Rayner AA, Linker CA, Schuman MA, Liu ET, Hohn DC. The role of splenectomy in multimodality treatment of thrombotic thrombocytopenic purpura. Ann Surg 1985;202:318-322
25. Veltman GA, Brand A, Leeksma OC, ten Bosch GJ, van Krieken JH, Briet E. The role of splenectomy in the treatment of relapsing thrombotic thrombocytopenic purpura. Ann Hematol 1995;70:231-236
26. Winslow GA, Nelson EW. Thrombotic thrombocytopenic purpura: indications for and results of splenectomy. Am J Surg 1995;170:558-561
27. Aqui NA, Stein SH, Konkle BA, Abrams CS, Strobl FJ. Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura. J Clin Apheresis 2003;18: 51-54
28. Islam MN, Iskander MN. Microtubulin binding sites as target for developing anticancer agents. Mini Rev Med Chem 2004; 4:1077-1104
29. Burns ER, Zucker-Franklin D. Pathologic effects of plasma from patients with thrombotic thrombocytopenic purpura on platelets and cultured vascular endothelial cells. Blood 1982;60:1030-1037
30. Gutterman LA. Treatment of TTP and HUS: the role of vincristine In: Kaplan BS, Trompeter RS, Moake JL Hemolyic Uremic Syndrome and Thrombotic Thrombocytopenic Purpua. New York: Dekker; 1992:513-530
31. [No author]. Treatment for thrombotic thrombocytopenic purpura: plasma, vincristine, hemodialysis and exchange transfusions. N Engl J Med 1978;298:971-972
32. Ziman A, Mitri M, Klapper E, Pepkowitz SH, Goldfinger D. Combination vincristine and plasma exchange as initial therapy in patients with thrombotic thrombocytopenic purpura: one institution's experience and review of the literature. Transfusion 2005;45:41-49
33. Dervenoulas J, Tsirigotis P, Bollas G, et al. Efficacy of intravenous immunoglobulin in the treatment of thrombotic thrombocytopaenic purpura. A study of 44 cases. Acta Haematol 2001;105:204-208
34. Castaman G, Rodeghiero F, Ruggeri M, di Bona E, Dini E. Long-lasting remission after high-dose intravenous immunoglobulins in a case of relapsing thrombotic thrombocytopenic purpura. Haematologica 1991;76:511-512
35. Kondo H, Imamura T. Effects of intravenous immunoglobulin in a patient with intermittent thrombotic thrombocytopenic purpura. Br J Haematol 2000;108:880-882
36. Chambers SA, Isenberg D. Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases. Lupus 2005;14:210-214
37. Fakhouri F, Teixeira L, Delarue R, Grunfeld JP, Veyradier A. Responsiveness of thrombotic thrombocytopenic purpura to rituximab and cyclophosphamide. Ann Intern Med 2004;140: 314-315
38. Fakhouri F, Vernant JP, Veyradier A, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13 deficient-thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005;106:1932-1937
39. Chemnitz J, Draube A, Scheid C, et al. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol 2002;71:105-108
40. Maloney DG. Concepts in radiotherapy and immunotherapy: anti-CD20 mechanisms of action and targets. Semin Oncol 2005;32(1 suppl 1):S19-S26
41. Ahmad A, Aggarwal A, Sharma D, et al. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP). Am J Hematol 2004;77:171-176
42. Gutterman LA, Kloster B, Tsai HM. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis 2002;28:385-391
43. Reddy PS, Deauna-Limayo D, Cook JD, et al. Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Ann Hematol 2005;84:232-235
44. Sallah S, Husain A, Wan JY, Nguyen NP. Rituximab in patients with refractory thrombotic thrombocytopenic purpura. J Thromb Haemost 2004;2:834-836
45. Stein GY, Zeidman A, Fradin Z, Varon M, Cohen A, Mittelman M. Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide. Int J Hematol 2004;80:94-96
46. Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai HM. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol 2004;124:787-795
47. Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med 2003;138:105-108
48. Galbusera M, Bresin E, Noris M, et al. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. Blood 2005;106:925-928
49. Bandarenko N, Stagg KF, Hay SN, Brecher ME. Cardiogenic shock complicates successful treatment of refractory TTP with rituximab. Transfusion 2004;4(9S):44A (abst)
50. Silverman GJ, Goodyear CS, Siegel DL. On the mechanism of staphylococcal protein A immunomodulation. Transfusion 2005;45:274-280
51. Nand S, Molokie R. Therapeutic plasmapheresis and protein A immunoadsorption in malignancy: a brief review. J Clin Apheresis 1990;5:206-212
52. Gaddis TG, Guthrie TH Jr, Drew MJ, Sahud M, Howe RB, Mittelman A. Treatment of plasma refractory thrombotic thrombocytopenic purpura with protein A immunoabsorption. Am J Hematol 1997;55:55-58
53. Drew MJ. Resolution of refractory, classic thrombotic thrombocytopenic purpura after staphylococcal protein A immunoadsorption. Transfusion 1994;34:536-538
54. Musio F, Bohen EM, Yuan CM, Welch PG. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin Arthritis Rheum 1998; 28:1-19
55. Creager AJ, Brecher ME, Bandarenko N. Thrombotic thrombocytopenic purpura that is refractory to therapeutic plasma exchange in two patients with occult infection. Transfusion 1998;38:419-423
56. Tarantolo SR, Landmark JD, Iwen PC, Kessinger A, Chan WC, Hinrichs SH. Bartonella-like erythrocyte inclusions in thrombotic thrombocytopenic purpura. Lancet 1997;350: 1602
57. Vesely SK, Li X, McMinn JR, Terrell DR, George JN. Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion 2004;44:1149-1158
58. Kojouri K, Vesely SK, George JN. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes. Ann Intern Med 2001;135:1047-1051
59. Bennett CL, Davidson CJ, Raisch DW, Weinberg PD, Bennett RH, Feldman MD. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med 1999;159:2524-2528
60. Zakarija A, Bandarenko N, Pandey DK, et al. Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke 2004;35:533-537
61. Dlott JS, Danielson CF, Blue-Hnidy DE, McCarthy LJ. Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a concise review. Ther Apher Dial 2004;8:102-111
62. Egan JA, Bandarenko N, Hay SN, et al. Differentiating thrombotic microangiopathies induced by severe hypertension from anemia and thrombocytopenia seen in thrombotic thrombocytopenia purpura. J Clin Apheresis 2004;19:125-129
63. Vesely SK, George JN, Lammle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102:60-68
64. Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol 2001;14:437-454